semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Malignant Tumors Informed consent Clinical diagnosis of advanced tumor stages of glioblastoma IV, metastasized sarcoma, as well as non small-cell lung carcinoma (NSCLC) IV  Pregnant patients
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Conditions or Focus of Study: *FDAAA (Enter 1 to 5 Items) Male or Female > 18 years, 2. Newly diagnosed stage I-IV breast cancer which is defined to meets any one of the following clinical or pathological staging (version 6.0 AJCC classification17) in Appendix B. 3. No prior therapy (other than surgery) for current disease, 4. Written informed consent (if required by local regulations)  Unable to receive definitive treatment 2. Unable to attend regular follow-up visit
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 16.0-26.0,  Cervical Cancer Cervical Intraepithelial Neoplasia Adenocarcinoma in Situ Healthy Japanese females Not pregnant at Screening and agree to use effective contraception through Month 7 of the study Lifetime history of 0 to 4 male or female sexual partners No oral temperature ≥37.5 centigrade within 24 hours prior to injection  Received a marketed HPV vaccine Prior abnormal Papanicolaou smear (PAP) or biopsy showing CIN Known history of positive test for HPV Known history of genital warts Received immune globulin or blood products within 6 months prior to first injection or plan to receive any through Month 7 of the study History of splenectomy, known immune disorders, or receiving immunosuppressives Immunocompromised or diagnosed as having human immunodeficiency virus (HIV)
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Patients must have a known or suspected cervical cancer Age >=18 years Patients must have no other active cancer at the time of diagnosis Patients must have no history of a hysterectomy Patients must be able to give informed consent Patients must be willing to undergo a biopsy of the cervical tumor to provide tissue for the study Patients must have completed a standard-of-care FDG-PET/CT prior to initiation of therapy, for assessment of lymph nodes  Pregnant women
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Uterine Cervical Neoplasms women 18 years old or older have recently received an abnormal Pap smear indicative of oncogenic HPV have been referred for initial colposcopic evaluation at the Women's Care Center at Temple University Hospital able to communicate with ease in English  unable to communicate readily in English do not have access to a telephone have a history of any malignancy display current evidence of positive invasive carcinoma of the cervix display presence of another life-threatening medical condition show evidence of dementia prior participation in research study HIV
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Uterine Neoplasms Sentinel Lymph Node Biopsy Women older than 18 years old 2. Endometrial cancer 3. Histologies: Grade 2 and 3 endometrioid adenocarcinoma, clear cell and papillary serous carcinoma 4. Suitable candidates for surgery 5. Clinically stage 1 or confined to the uterus  Grade 1 endometrioid adenocarcinoma 2. Metastatic disease
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 30.0-45.0,  HPV Infection pathologic Pap smear positive "high risk" HPV DNA test positive colposcopy examination  patients who had undergone wart therapy in the previous six months pregnancy invasive disease immunosuppression previous HPV vaccination
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 25.0-70.0,  Cervical Cancer Somali female age 25-70 years have lived in the U.S. 10 years or less have not had a Pap test (by self report) in the last 3 years  Women with a self reported past history of any of the following will not be eligible total hysterectomy cervical cancer active history of cervical dysplasia
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 30.0-65.0,  Cervical Cancer Human Papillomavirus Infection Women from 30 to 65 years Living in Indre-et-Loire (french territorial division 37)  Women who attend organized cervical cancer screening or who answer to the invitation Cervical smear made in the three last years HPV linked cervical condition undergoing treatment Hysterectomy (including cervix)
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  IBD i. Women and men between the ages of 18-65 with a history of inflammatory bowel disease confirmed histologically and on immunosuppression defined as at least three months of azathioprine/6MP, eight consecutive weeks of prednisone greater than 15mg per day, a cumulative dose of greater than 100mg of methotrexate, or at least one infusion of infliximab within 8 weeks of the date of the anal Pap smear. ii. Women and men between the ages of 18-65 with a history of inflammatory bowel disease confirmed histologically and not on immunosuppression (defined as above)  i. Patients with HIV, transplant recipients, men who have sex with men as they already represent high risk groups ii. Women with a history of an abnormal cervical Pap test within the past 2 years. iii. Patients with active proctitis as defined by an abnormal sigmoidoscopy or colonoscopy, rectal bleeding or tenesmus
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Human Papillomavirus Aged 18-50 years Had recent Pap smear result consistent with HSIL or "cannot rule out HSIL" or HSIL on biopsy Untreated for HSIL or "Cannot rule out HSIL" Able to provide informed consent Certain physical exam and blood component parameters within acceptable ranges Willingness and able to comply with the requirements of the protocol with a good command of the English language  History of disease or treatment causing immunosuppression (e.g., cancer, HIV, organ transplant, autoimmune disease) Being pregnant or attempting to be pregnant within the period of enrollment Breast feeding or planning to breast feed within the period of enrollment Allergy to Candida antigen History of severe asthma requiring emergency room visit or hospitalization Current use of beta-blocker medication (may not respond to epinephrine in case of anaphylaxis) If in the opinion of the Principal Investigator or other Investigators, it is not in the best interest of the patient to enter this study
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Histologically confirmed adenocarcinoma, squamous, or adenosquamous cancer of the cervix. Diagnosis has been made by LEEP, cone or cervical biopsy and has been reviewed and confirmed by the local reference gynecological pathologist Patient has been classified as low-risk early-stage cervical cancer. These patients • FIGO Stage IA2 [FIGO Annual Report, 2009], defined as: o evidence of disease by microscopy for patients who underwent a LEEP or cone histologic evidence of depth of stromal invasion > 3.0 and ≤ 5.0 mm based on the local reference pathologist's measurement of the LEEP or cone specimen histologic evidence of lateral extension that is ≤ 7.0 mm based on the local reference pathologist's measurement of the LEEP or cone specimen; and negative margins (patients with positive margins are considered IB1, see below) for patients who underwent a cervical biopsy only radiologic evidence of less than 50% stromal invasion based on pelvic MRI • FIGO Stage IB1 [FIGO Annual Report, 2009] with favorable (low risk) features, defined as measured stromal invasion and lateral extension that meet the for IA2 (see above) but with positive margins evidence of disease by clinical exam; lesion must clinically measure ≤ 20 mm  Patients with FIGO 1A1 disease [FIGO Annual Report, 2009] History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours, Hodgkin's lymphoma or non-Hodgkin's lymphoma curatively treated with no evidence of disease for > 5 years Patients with evidence of lymph node metastasis on preoperative imaging or histology Patients who have had or will receive neoadjuvant chemotherapy Patients who are pregnant
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Uterine Cervical Cancer Cervical cancer, advanced or recurrent metastasis Measurable and assessible tumor lesions Used ordinary paclitaxel or platinum drugs, more than 28 days Aged 18-70 KPS score> 60 points, expected to survive more than 3 months Normal bone marrow function The function of liver and kidney had no obvious damage Normal function of vital organs No brain metastases Patients or their agents to sign informed consent  Brain metastases Serious complications Acute inflammatory response Combined with other tumor Pregnancy or breast-feeding women Vertebral metastasis with nerve compression symptoms Large volume of pleural effusion, pericardial effusion Other malignancy within five years Drug allergy Other chemotherapy contraindications
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Uterine Cervical Neoplasms Referred to follow up due to one or more abnormal Pap or an HPV infection Subjects who have provided informed consent Subjects who meet the minimum age set forth by the ethics committee (EC) and/or national screening guidelines  Known to be pregnant With prior complete or partial hysterectomy involving removal of cervix Subjects with an application of chemical compounds to the cervical area 24 hour prior to study entry this includes acetic acid, iodine, spermicide, douche, anti-fungal meds Subjects on who conization, Loop electrosurgical excision procedure (LEEP), laser surgery or cryosurgery has been performed
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-75.0,  Cervical Cancer Previously untreated, histologically confirmed cervical cancer FIGO stage IB2 and IIA2 disease One of following histologic types 1. Squamous cell carcinoma 2. Adenocarcinoma 3. Adenosquamous carcinoma Gynecologic Oncology Group performance status: 0-2 Adequate organ function 1. Bone marrow: WBC > 3000/mm3, ANC ≥ 1,000/mm3, Platelet ≥ 100*103/mm3, Hemoglobin ≥ 10g/dL 2. Kidney: Creatine < 1.25 * upper normal limit 3. Liver: AST, ANT < 3 * upper normal limit, Total bilirubin < 1.5 mg/mm3 Patient who have Singed an approved informed consent  Patients with cervical cancer who have received any previous radiation or chemotherapy Neuroendocrine carcinoma of uterine cervix Occult cervical cancer which was found after simple hysterectomy Para-aortic nodal involvement (> 10 mm short axis diameter on pretreatment imaging study) History of other invasive malignancies, with the exception of non-melanoma skin cancer, in situ melanoma and thyroid cancer, who had (or have) no evidence of the other cancer present within the last 5 years Serious illness or medical condition that precludes the safe administration of the trial treatment including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements Prior diagnosis of Crohn's disease or ulcerative colitis Neurologic or psychiatric disease Patients who are pregnant or lactating
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Human Papillomavirus Infection Subjects who were previously enrolled into the prospective, multicenter US clinical study for the HPV Assay on the System (protocol 2007HPVASCUS30) will be eligible for in the study of the AHPV-GT Assay using the System described in this protocol. All evaluable ASC-US Study subjects ≥21 years of age will be eligible for inclusion. Evaluable Adjunct Study subjects ≥30 years of age will be eligible if the following are met the subject attended the colposcopy visit, or the subject did not attend the colposcopy visit but the referral Pap sample had a positive HPV Assay result in the HPV Assay System study (protocol 2007HPVASCUS30) or in the HPV Assay System study (protocol  Eligible subjects will be excluded if they do not have an evaluable sample. This may be due to insufficient volume or because the sample was deemed unsuitable for testing (eg, stored under unacceptable conditions)
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Human Papillomavirus Infection Female subjects vaccinated with either HPV-1 or HPV-2 vaccines in Taiwan (hypothetical group)  Not applicable
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Intimate Partner Violence She is 18 or older She is currently court supervision at Bronx Community Solutions or a drug treatment court or she is currently on probation She reports using any illicit drug or drinking 4 or more alcoholic drinks in a 6-hour period in the past 90 days or she has been in alcohol or drug treatment in the past 6 months OR if she report attending any drug or alcohol treatment in the past 6 months She reports having had an ongoing intimate, dating or sexual relationship with a male or female partner that lasted 3 or more months in the past year She lives within a 90-minute commute of 125th and Broadway  Ability to speak and understand English is not sufficient to participate in assessments or intervention sessions Inability to complete informed consent process due to a psychiatric or cognitive impairment The participant is unwilling or unable to commit to completing all the activities in the study
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer HIV infected women, older than 18 years of age, followed in the PHPT cohort  Virginity, total hysterectomy, pregnancy after 3rd month, in a HPV vaccination trial
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Histologically proven cervical cancer: squamous cell carcinoma or adenocarcinoma; FIGO stages IB IIA (preoperatively); Karnofsky-Index ≥ 70; unrestricted operability; BMI <35; age >=18 years Individual decision for treatment of TMMR and therapeutic LNE without adjuvant radiotherapy by the responsible clinic (clinician) on a clinical routine basis Informed consent of the patient  Neuroendocrine differentiation and all preoperative FIGO stage IA or >IIA Distant metastases except in para-aortic lymph nodes; sclerodermia, lupus erythematodes, mixed connective tissue disease; secondary malignancy; previous radiotherapy of the pelvis Patients with diseases of the connective tissue will be excluded because of unforeseeable (e.g. neurological) symptoms and disorders after surgery. Patients with a BMI ≥ 35 will be excluded because of very high risks regarding wound healing, infections and thrombosis independent on the type of surgery
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Human Papillomavirus Infection Couple must have been in a new relationship that started no more than six months prior to study entry Both partners plan on remaining in Montreal for at least 1 year Plan on having continued sexual contact with partner Be willing to comply with study procedures  Volunteers must not have been vaccinated against HPV-Gardasil-9 (both partners) Any history of cervical, penile, oral or anal cancers Being pregnant or plan on immediately becoming pregnant